

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **东曜药业**

### **TOT BIOPHARM International Company Limited**

**東曜藥業股份有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1875)**

### **DELAY IN DISPATCH OF CIRCULAR IN RESPECT OF CONNECTED TRANSACTION INVOLVING ISSUE OF NEW SHARES UNDER SPECIFIC MANDATE TO TRUSTEE HOLDING SHARES ON TRUST FOR CONNECTED PERSONS**

Reference is made to the announcement of TOT BIOPHARM International Company Limited (the “**Company**”) dated 1 November 2022 in relation to the connected transaction involving the issue of new Shares under specific mandate to a trustee holding Shares on trust for connected persons (the “**Announcement**”). Unless otherwise stated, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

As set out in the Announcement, a circular (the “**Circular**”) containing, among other things, (i) further details of the Connected Grant and the allotment and issue of the Connected Grant Shares; (ii) a letter of advice from the independent Board committee; (iii) a letter of advice from the Independent Financial Adviser; and (iv) the notice of the Extraordinary General Meeting, was expected to be dispatched to the Shareholders on or before 22 November 2022.

As additional time is required for the Company and its advisers to prepare and finalize certain information to be included in the Circular, the Company now expects to dispatch the Circular to the Shareholders on or before 2 December 2022.

By order of the Board  
**TOT BIOPHARM International Company Limited**  
**Dr. Liu, Jun**  
*Chief Executive Officer and Executive Director*

Hong Kong, 24 November 2022

*As at the date of this announcement, the executive directors of the Company are Dr. Liu, Jun and Ms. Yeh-Huang, Chun-Ying; the non-executive directors of the Company are Mr. Fu, Shan and Mr. Qiu, Yu Min; and the independent non-executive directors of the Company are Ms. Hu, Lan, Mr. Chang, Hong-Jen and Dr. Wang, De Qian.*